Novartis / Immunovaccine Inc. / HISTORY AND STRATEGY History The Company / Merck KGaA / Dendreon / GlaxoSmithKline / Sanofi / Merck & Co. / A. COMPANY OVERVIEW Immunovaccine / Pfizer / TSX Venture Exchange / CSL Limited / Sanofi Pasteur / /
Continent
Europe / North America / /
Country
Canada / United States / /
Currency
USD / /
Event
Business Partnership / Funding / M&A / FDA Phase / /
Facility
Weill Cornell Medical College / Dalhousie University / NIH’s National Institute of Allergy / Canadian Institute of Chartered Accountants / fill/lyophilization facility / National Cancer Institute / /
IndustryTerm
existing and new products / manufacturing facility / human applications / treatment of ovarian cancer / pharmaceutical industry / cancer therapy / platform technology / vaccine products / manufacturing processes / vaccine delivery technology / manufacturing process / treatment of cancer / contract manufacturing formulation / manufacturing / healthcare providers / livestock vaccine applications / animal health vaccine applications / biotechnology / delivery technology / oil phase / manufacturing practices / compromised immune systems / cancer treatment / pharmaceutical / oil / product-specific manufacturing process / licensable products / sterile products / treatment of multiple solid tumors and hematological cancers / scale manufacturing process / contract manufacturing facility / enhancement technology / /
MedicalCondition
ovarian cancer / H5N1 pandemic influenza / infectious and other diseases / therapeutic cancer / hepatitis B / H5N1 influenza / clinical-stage cancer / melanoma / prostate cancer / breast cancer / glioblastoma / tumor / Conventional cancer / cancer / tumors / Immunovaccine’s therapeutic cancer / human cancer / difficult infectious and other disease / cocaine addiction / diseases / melioidosis / ovarian and prostate cancer / pancreatic / multiple myeloma / anthrax / hematological cancers / drug addiction / Therapeutic cancer vaccines Cancer / advanced ovarian cancer / successful therapeautic cancer / solid tumors / widespread and prevalent diseases / several cancers / disease / pertussis / prostate and ovarian cancer / Infectious Diseases A / critical tumor / pandemic influenza / infectious diseases / B-cell lymphoma / Several first-in-class therapeutic cancer / /
MedicalTreatment
vaccination / surgery / immunotherapy / radiation / cancer therapy / contraception / chemotherapy / /
Organization
National Institute on Drug Abuse / Department of Fisheries and Oceans / Canadian Institute of Chartered Accountants / Dalhousie University / National Cancer Institute / National Institute of Health / NIH’s National Institute of Allergy and Infectious Diseases / International Accounting Standards Board / Scientific Advisory Board / U.S. Food and Drug Administration / Atlantic Canada Opportunities Agency / Department of Defense / Weill Cornell Medical College / U.S. Centers for Disease Control and Prevention / /
Person
John Trizzino / /
Position
CEO 1 MANAGEMENT / scientific advisors / investigator / /
Microsoft Word - Q2 - MD&A - final to be filed.docx